XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2
Business Segments and Geographic Information
 9 Months Ended
Jun. 29, 2024
Segment Reporting [Abstract]  
Business Segments and Geographic Information Business Segments and Geographic Information
The Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges (such as intangible asset amortization expense, and goodwill and intangible asset impairment charges), transaction and integration expenses for acquisitions, restructuring, consolidation and divestiture charges, litigation charges, and other one-time or unusual items.
Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three and nine months ended June 29, 2024 and July 1, 2023. Segment information is as follows:

 Three Months EndedNine Months Ended
 June 29,
2024		July 1,
2023		June 29,
2024		July 1,
2023
Total revenues:
Diagnostics$440.8 $439.7 $1,338.7 $1,463.6 
Breast Health385.0 360.3 1,147.3 1,079.9 
GYN Surgical166.6 157.3 484.8 456.2 
Skeletal Health19.0 27.1 71.5 85.4 
$1,011.4 $984.4 $3,042.3 $3,085.1 
Income from operations:
Diagnostics$89.7 $(113.5)$210.1 $142.8 
Breast Health102.4 63.3 296.2 233.7 
GYN Surgical56.7 48.5 144.3 149.6 
Skeletal Health(4.8)3.1 2.0 9.8 
$244.0 $1.4 $652.6 $535.9 
Depreciation and amortization:
Diagnostics$51.0 $56.8 $168.3 $172.9 
Breast Health9.3 12.2 29.6 38.7 
GYN Surgical11.9 11.9 36.1 35.8 
Skeletal Health0.1 0.3 0.4 0.5 
$72.3 $81.2 $234.4 $247.9 
Capital expenditures:
Diagnostics$17.7 $22.6 $61.7 $58.7 
Breast Health10.4 8.0 25.1 22.0 
GYN Surgical4.8 4.5 11.5 11.2 
Skeletal Health0.7 — 1.1 0.2 
Corporate0.3 1.4 0.5 5.6 
$33.9 $36.5 $99.9 $97.7 
 
June 29,
2024		September 30,
2023
Identifiable assets:
Diagnostics$2,476.3 $2,596.4 
Breast Health1,217.6 1,170.1 
GYN Surgical1,429.8 1,455.4 
Skeletal Health35.6 33.7 
Corporate3,730.8 3,883.7 
$8,890.1 $9,139.3 

The Company had no customers that represented greater than 10% of consolidated revenues during the three and nine months ended June 29, 2024 and July 1, 2023.

The Company operates in the following major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from the United Kingdom, Germany, France, Spain, Italy and the Netherlands. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East.
Revenues by geography as a percentage of total revenues were as follows:
 
 Three Months EndedNine Months Ended
 June 29,
2024		July 1,
2023		June 29,
2024		July 1,
2023
United States75.7 %76.2 %74.9 %75.9 %
Europe12.6 %13.1 %13.4 %13.9 %
Asia-Pacific6.4 %6.4 %6.4 %6.2 %
Rest of World5.3 %4.3 %5.3 %4.0 %
100.0 %100.0 %100.0 %100.0 %